Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Bioverativ

Biotech & Life Sciences · Waltham, United States · Founded 2016 Decacorn

Global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders

Valuation
$10–50B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value

Global footprint

Where Bioverativ has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States82.1%
🇯🇵 Japan17.9%
2 countries shown

Patent intelligence

$314M patent portfolio · 101 active families

Estimated portfolio value
$314M
2.7% of valuation · 6.5× smaller than top peer Ablynx ($2B)
101 active patent families
Where Bioverativ innovates Molecular biologyAntiendomysial antibodiesImmunologyAnti antibodyDisease

Where Bioverativ concentrates vs peers

Each axis is a top-10 topic across Bioverativ and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Bioverativ's 1 investments and acquisitions.

Every disclosed deal where Bioverativ appeared as a backer or acquirer, 2017–2017. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

1 deals across Bioverativ's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Bioverativ deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Bioverativ's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        1 of 1 deals

        Market sentiment

        What the market is saying about Bioverativ

        An AI-synthesized read of the highest-engagement posts about Bioverativ on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Bioverativ on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.